Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present MOTIF BIO PLC (NASDAQ: MTFB).

Full DD Report for MTFB

You must become a subscriber to view this report.


Recent News from (NASDAQ: MTFB)

Motif Bio to participate at upcoming Jefferies London Healthcare Conference
NEW YORK, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company will participate in the following event: Jefferies London Healthcare Conference Nove...
Source: GlobeNewswire
Date: October, 31 2018 03:00
Motif Bio to Present Iclaprim Data at Upcoming Scientific Conferences
NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be presented at two upcoming scientific conferences. IDWeek 2018 October 3-7,...
Source: GlobeNewswire
Date: September, 20 2018 02:00
Danforth Advisors Names Robert Dickey IV Managing Director, Mid Atlantic Region
SOMERVILLE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Danforth Advisors, LLC, specialists in accounting, finance support and strategy for life science and healthcare companies, today announced additional regional leadership and support with the appointment of Robert Dickey IV as Managing Di...
Source: GlobeNewswire
Date: September, 11 2018 08:00
Motif Bio Presents Iclaprim Data at ESCMID/ASM Conference
Iclaprim overview presented in State of the Art Lecture Safety analysis of diabetic patients in REVIVE ABSSSI trials shows fewer adverse events versus vancomycin Surveillance data confirm in vitro activity of iclaprim against wide variety of Gram-positive bacteria, including drug-resi...
Source: GlobeNewswire
Date: September, 05 2018 02:00
Motif Bio to Present Iclaprim Data at ESCMID/ASM Conference
NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be presented at the upcoming European Society of Clinical Microbiology and Infectiou...
Source: GlobeNewswire
Date: August, 17 2018 02:00
Your Daily Pharma Scoop: Motif Bio NDA Under Review, MiMedx Nixed, Biogen Halts
Stocks in News: MTFB, MDXG FDA accepts Motif Bio's NDA with priority review for Iclaprim Discussion : FDA accepted for filing the NDA of Motif Bio’s ( MTFB ) iclaprim. Iclaprim is a gram-positive investigational antibiotic, targeted for the treatment of acute bacterial skin and...
Source: SeekingAlpha
Date: August, 16 2018 09:08
3 Things In Biotech, August 15: Motif Looks To Advance A Safer Antibiotic For Skin Infection
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. AVEO partner moves forward with a HER3 treatment in China Company: CANbridge Life Scien...
Source: SeekingAlpha
Date: August, 15 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-14N/A8.50N/AN/A71

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-135050100.0000Short
2018-12-1210045022.2222Cover
2018-12-1028038073.6842Short
2018-12-0321823692.3729Short
2018-11-287002,00035.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MTFB.


About MOTIF BIO PLC (NASDAQ: MTFB)

Logo for MOTIF BIO PLC (NASDAQ: MTFB)

Motif Bio is a clinical stage biopharmaceutical company which specializes in developing novel antibiotics designed to be effective against serious and life threatening infections caused by multi drug resistant bacteria.

 

Contact Information

 

 

Current Share Structure

     


    Recent Filings from (NASDAQ: MTFB)

    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: August, 21 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: August, 14 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: August, 08 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: July, 03 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: June, 19 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: June, 14 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 23 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 17 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 09 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 19 2018

     

     


    Daily Technical Chart for (NASDAQ: MTFB)

    Daily Technical Chart for (NASDAQ: MTFB)


    Stay tuned for daily updates and more on (NASDAQ: MTFB)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: MTFB)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MTFB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MTFB and does not buy, sell, or trade any shares of MTFB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/